Ouyi Technology has recently declared the successful closure of a Series C funding round, amassing 150 million yuan. This round was spearheaded by the CICC Brain Science Fund, with ongoing support from several existing shareholders. Since its inception in 2015, Ouyi Technology has committed itself to the research and development of non-invasive neural signal sensing and AI analysis technologies. The company proudly showcases a range of self-developed products and holds over a hundred independent intellectual property rights.

With the brain-computer interface and embodied intelligence sectors benefiting from favorable policy shifts, the CICC Brain Science Fund—a specialized fund dedicated to the brain science and brain-inspired intelligence industries within Shenzhen's '20+8' industrial cluster strategy—has joined forces with Ouyi Technology. This collaboration has formed a robust shareholder base, blending 'professional brain science funds with industrial players from medical listed companies'.

In terms of product innovation, Ouyi Technology has pioneered a 'brain-muscle-machine' technological pathway, expediting the integration of non-invasive brain-computer interface technologies in neurorehabilitation settings. Its ORF series rehabilitation exoskeletons have gained widespread adoption in reconstructing patients' motor functions. In the realm of embodied intelligence, the ROHand series dexterous hands have seen a steady increase in shipments, catering to nearly a hundred humanoid robot clients.

Presently, Ouyi Technology's products have been deployed in numerous top-tier hospitals nationwide and supplied in bulk to leading manufacturers. The company's performance has doubled over the past three years, with the scale and growth rate of its overseas operations eclipsing those of the domestic market. Addressing the nuances of overseas markets, CEO Ni Hualiang emphasized the need for the company to refine and adapt its products and services.